
SK Bioscience Expanding Covid Vaccine Output
South Korea-based CDMO SK Bioscience, with cash in hand from an initial public offering, has announced plans to pour 150 billion won ($132 million) into vaccine production up to 2024, which will mean to adding some 99,130 m2 of production space and equipping its plant at Andong to make newer mRNA- and viral vector-based Covid-19 vaccines.






































